Tolmar Inc.

Quick facts

Marketed products

• Anastrozole Tablets · Oncology
  Anastrozole inhibits the enzyme aromatase, which converts androgens to estrogen in postmenopausal women, thereby reducing circulating estrogen levels to treat hormone receptor-positive breast cancer.
• Taclonex · Other

Phase 3 pipeline

• Exemestane Tablets · Oncology
  Exemestane is a steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer.
• TOL2506 · Oncology
  TOL2506 is a long-acting leuprolide acetate formulation designed to suppress luteinizing hormone and testosterone levels.

Phase 1 pipeline

• Calcipotriene and betamethasone suspension

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Tolmar Inc. portfolio CI brief
• Tolmar Inc. pipeline updates RSS